Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
To investigate, in a double-blind randomized controlled trial, whether initiating treatment
with ultra-low-dose quadruple-combination therapy ("LDQT") will lower office blood pressure
more effectively, and with fewer side effects, compared to initiating standard dose
monotherapy as per current guidelines in patients with hypertension.
Primary hypothesis: A combination pill comprising four types of blood pressure lowering
medications, each at one-quarter standard doses, will lower office blood pressure more
effectively than initiating patients with standard dose monotherapy as per contemporary
clinical practice guideline recommendations.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
ACCESS Community Health Network University of Sydney
Treatments:
Candesartan Candesartan cilexetil Ethinyl estradiol, levonorgestrel drug combination